Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#3020 Outcomes Following Surgical Management of Pulmonary Carcinoids – A Tertiary Center Experience
Introduction: Pulmonary carcinoids are a rare type of malignant lung tumour. Surgery forms the mainstay of management when operable. However, there is paucity of data on conservative management and effective follow-up strategies.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Hoshen M
Authors: Hoshen M, Nallathambi C, Mohan Das L, Clarke K, Robson J,
Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Keywords: 177Lu-DOTATATE, metastases, quality of life,
Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Oberg K
Authors: Öberg K, Califano A, Strosberg J, Ma S, Pape U,
Keywords: NETest, Meta-analysis, biomarker, in vitro diagnostic, diagnostic, management, NET, AUC, ROC,
Introduction: DIPNECH is characterized by a proliferation of pulmonary neuroendocrine cells and multifocal neuroendocrine tumorlets and/or tumors. Although usually indolent, DIPNECH can cause chronic cough and dyspnea. There is very limited information on treatment.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Al-Toubah T, Strosberg J, Halfdanarson T, Oleinikov K, Gross D,
Keywords: DIPNECH, Somatostatin analogs, Octreotide, Lanreotide,
Introduction: New systemic treatments have improved the therapeutic landscape for patients with progressive, metastatic GEP-NETs. While drugs such as everolimus are appropriate for patients with widespread disease progression, local treatment approaches may be more appropriate for patients with unifocal progression.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Strosberg J
Authors: Al-Toubah T, Cives M, Anaya D, Soares H, Strosberg J,
Keywords: GEP-NET, locoregional treatment, ablation, embolization, surgical resection, neuroendocrine tumor, systemic therapy, external beam radiation,